AzTrials
AzTrials

Cardiometabolic HealthVeganBurgerNCT05582720

Cardioprotective Properties of Vegan Burger

A study testing Conventional burger and Vegan burger in people with Cardiometabolic Health, run by Harokopio University at 1 site in Greece.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Several studies over the last decades have demonstrated the important role of nutrition in the development of chronic diseases, such as cardiovascular disease and cancer. One dietary component that has been in the center of scientific research is red meat and processed meat (e.g., cold cuts, sausages, burgers). Read more about this study

Who is it for?
Ages 30 to 60 yearsHealthy volunteers can take part
Conditions the study is for
Cardiometabolic Health
What is being tested?
Conventional burger and Vegan burger
Could I receive a placebo?
No, everyone receives an active treatment
How many people
15 participants
Where
1 siteGreece
Study dates
1 Oct 2022to May 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Age 30-60 years old
  • Body mass index ≥25 kg/m2
  • Habitual red meat consumption ≥3 portions/week (1 portion: 120 g cooked meat)

Who cannot join

  • Presence of chronic diseases, such as diabetes mellitus, active cancer, cardiovascular, liver kidney, respiratory, gastrointestinal, chronic inflammatory and psychiatric diseases
  • Reception of immunosuppressant, anti-inflammatory or cortisol medication,
  • Intake of protein, amino acid, fatty acid, dietary fiber, probiotic and prebiotic supplements
  • Habitual excessive alcohol consumption, i.e., >210 g and >140 g of ethanol per week for men and women, respectively
  • Currently being on a restrictive diet (e.g., weight loss or vegetarian diet) or any significant recent change (within 6 months) in lifestyle habits
  • Pregnancy and breastfeeding for women

Trial locations and contacts

1 site in 1 country.

Tzortzis Nomikos, PhD contact

+302109549100 ext. 305

tnomikos@hua.gr

Michael Georgoulis, PhD contact

+302109549100 ext. 329

mgeor@hua.gr

Greece1 site, 1 recruiting
  • Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University

    Kallithea, Attica, 17676

    Tzortzis Nomikos, PhD, +302109549100 ext. 305, tnomikos@hua.gr

    Michael Georgoulis, PhD, +302109549100 ext. 329, mgeor@hua.gr

    Recruiting

Other trials in Greece

About this study

Official title: Development of Innovative Functional Meat Analogues Using Alternative Sources of Plant Proteins and Novel Technologies

Several studies over the last decades have demonstrated the important role of nutrition in the development of chronic diseases, such as cardiovascular disease and cancer. One dietary component that has been in the center of scientific research is red meat and processed meat (e.g., cold cuts, sausages, burgers). Burger, in particular, is one of the most popular red meat products and its consumption has increased rapidly in recent years due to the expansion of fast-food restaurants, its wide availability and its low price. However, due to its high animal fat content which is mostly saturated and high degree of processing, its nutritional value and the safety of its long-term high consumption have been questioned. The wide acceptance of burger by the general population, combined with the perception that it is a "burdensome" food for health, makes it an ideal subject for interventions aiming at modifying its nutritional value without downgrading its organoleptic characteristics and increasing its cost. Such an approach could be applied to the meat industry in order to develop innovative, functional meat analogues of high nutritional and organoleptic value, which could find acceptance by both meat-eating and vegetarian/vegan populations. Therefore, the aim of the present double-blind, randomized, crossover clinical trial is to explore the potential cardioprotective properties of "vegan burger", a novel meat analogue developed through the substitution of animal proteins and lipids with plant-based constituents using innovative technologies, against the conventional animal-based burger, in apparently healthy volunteers.

Read the detailed description

The nutritional value and health effects of red meat and processed meat products (e.g., cold cuts, sausages, burgers) remain the object of intense research and scientific controversy in the fields of Nutrition and Food Science. Red meat is a rich source of macronutrients (e.g., proteins of high biological value) and several micronutrients (e.g., iron), and a food group particularly appealing to consumers. However, in recent years there has been an increase in the total consumption of red meat and processed meat products in developed countries, which has been associated with both increased risk of chronic diseases (e.g., cardiovascular diseases, obesity, diabetes mellitus, various types of cancer and autoimmune diseases) and increased total mortality. The aggravating effect of red meat consumption on health is likely attributed to its increased content of saturated fatty acids, which have been associated with the occurrence of insulin resistance, dyslipidemia, and disturbances in the intestinal microbiota, as well as other components produced during its processing (e.g., oxidized forms of fat, heterocyclic amines, polycyclic aromatic hydrocarbons), which can trigger mechanisms of inflammation, oxidative stress and carcinogenesis, and further contribute to the pathogenesis of cardiometabolic and neoplastic diseases. Based on the available research data, scientific associations and health organizations at the local and international level recommend limiting the consumption of red meat and meat products and replacing them with products of plant origin in the context of adopting a balanced health-promoting diet and reducing the risk of chronic cardiometabolic disorders in the general population.

Burger is one of the most popular meat products and its consumption has increased rapidly in recent years due to the expansion of fast-food restaurants, its wide availability and its low price. However, due to its high content in animal fat, which is mostly saturated, its nutritional value and the safety of its long-term high consumption have been questioned. The wide acceptance of burger by the general population, combined with the perception that it is a "burdensome" food for health, makes it an ideal subject for interventions aiming at modifying its nutritional value without simultaneously degrading its organoleptic characteristics and increasing its cost. Such an approach could be applied to the meat industry in order to develop innovative, functional meat analogues of high nutritional value, which could also find acceptance by meat-eating populations. The challenges in this direction are many, such as the reduction of lipids and/or the replacement of saturated fatty acids with other health-beneficial lipids without degrading the texture and taste of the product, and the replacement of animal proteins with plant proteins. Until now, the majority of commercially available meat analogs are made from soy protein or gluten. However, protein products have also been developed from other raw materials, including vegetables and legumes (e.g., peas and chickpeas). In addition, protein products from fungi and bacteria are available, which are suitable for reproducing the taste and texture of meat. Regarding fat, various ingredients have also been explored as substitutes for animal fat, such as dietary fiber and vegetable oils.

The aim of the present study is to explore the potential cardio-protective effects of an innovative burger of high nutritional and organoleptic value (vegan burger), developed through the substitution of animal proteins and lipids with plant-based constituents using innovative technologies, compared to a conventional burger, in apparently healthy subjects.

The study will be a randomized, cross-over, double blind clinical trial. The study sample will consist of 15 apparently healthy subjects aged 30-60 years, with a body mass index of ≥25 kg/m2 and a habitual red meat consumption of ≥3 times/week. Candidates will be excluded from the study on the basis of the following: i) presence of chronic diseases, such as diabetes mellitus, active cancer, cardiovascular, liver kidney, respiratory, gastrointestinal, chronic inflammatory and psychiatric diseases; ii) use of certain types of medication, i.e., immunosuppressants, anti-inflammatory drugs and cortisol, and dietary supplements, i.e., protein, amino acids, fatty acids, dietary fiber, probiotics and prebiotics (other prescribed medications and micronutrient supplements will be allowed, provided that their reception will remain stable throughout the trial); iii) habitual excessive consumption of alcohol (>210 g and >140 g of ethanol per week for men and women, respectively), iv) currently being on a restrictive diet (e.g., weight loss or vegetarian diet) or any significant recent change (within 6 months) in lifestyle habits, and v) pregnancy and breastfeeding for women.

Participants will be randomized to consume 2 servings per week of either a conventional burger or a vegan burger (serving size: 150 g of raw product corresponding to 120 g of cooked product) for 4 weeks, with a 2-week wash-out period between the two interventions. Randomization will be performed by a researcher with no clinical involvement in the study and will be blind to all members of the research team.

All burger products will be prepared by a certified food industry (Hellenic Catering S.A.) based on current food safety legislation and quality assurance specifications. The conventional burger will be the animal(beef)-based burger already produced and marketed by the company, while the experimental burger (vegan burger) will be developed using innovative technologies from plant-based products, such as proteins and dietary fibers from legumes and edible strains of basidiomycetes, lipids of plant origin rich in n-3 polyunsaturated fatty acids and other bioactive components. The development of the methodologies for the isolation of the raw materials will be performed by the Laboratory of Design and Process Analysis, School of Chemical Engineering, National Technical University of Athens and the Laboratory of Biotechnology, Department of Biological Applications \& Technology, University of Ioannina. The development of the experimental vegan burger to be used in the dietary intervention will take place in a pilot unit of Hellenic Catering S.A. A product preparation will be designed with the incorporation of vegetable proteins from meat analogues, with the aim of the final product composition meeting the desired technical characteristics of structure and texture as well as the organoleptic characteristics of a burger. An appropriate mold and molding machine will be selected to shape the product, and appropriate packaging, preservation and processing methods (e.g., sock freezing, chilling, cooking) will be utilized. The two burger products will have a common shape and organoleptic characteristics (odor, texture and taste).

Participants will be given additional instructions to maintain their usual dietary intake, physical activity level, prescribed medications and dietary supplements, as well as to refrain from any weight loss effort throughout the study. The study physician will be on a weekly contact with each participant to systematically record potential side-effects and will be in charge of terminating the intervention if needed. Participants' adherence to the intervention will be assessed through weekly self-monitoring diaries, in which subjects will record the day of consumption, the quantity and the cooking method of the burger products, along with other dietary characteristics and the use of medications and dietary supplements. Participants will be evaluated at the start and at the end of each intervention period (total of 4 evaluations) in terms of anthropometric indices, body composition, and lifestyle habits (diet and physical activity) through validated questionnaires, while fasting blood and first-morning urine samples will be taken to determine laboratory parameters (glucose metabolism indices, lipidemic profile, liver enzymes, inflammatory and oxidative stress markers, etc.). All biological samples will be collected and analyzed in the Laboratory of Clinical Nutrition and the Laboratory of Biology, Biochemistry, Physiology and Microbiology, Department of Nutrition and Dietetics, Harokopio University of Athens, by experienced personnel.

Being tested
Conventional burger, Vegan burger
Keywords
read meat, meat analogues, burger, vegan burger, dietary intervention, plant proteins, inflammation, oxidative stress, thrombosis, cardioprotection
Medical subject headings
Inflammation, Thrombosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Conventional burgerBehavioural

    Participants initially randomized to this intervention arm will be provided with a total of 8 conventional burgers and will be asked to consume them twice weekly for 4 weeks. Conventional burgers will be produced by Hellenic Catering S.A. using standard procedures. Participants will also be instructed to maintain their usual dietary intake, physical activity level, prescribed medications and dietary supplements, as well as to refrain from any weight loss effort during the intervention. After a 2-week wash-out period (no burger consumption), participants will cross over to the other intervention arm.

  • Vegan burgerBehavioural

    Participants initially randomized to this intervention arm will be provided with a total of 8 vegan burgers and will be asked to consume them twice weekly for 4 weeks. Vegan burgers will be produced by Hellenic Catering S.A. using novel technologies. Participants will also be instructed to maintain their usual dietary intake, physical activity level, prescribed medications and dietary supplements, as well as to refrain from any weight loss effort during the intervention. After a 2-week wash-out period (no burger consumption), participants will cross over to the other intervention arm.

Study groups in NCT05582720
Study groupRoleWhat they receive
Conventional burger groupActive comparatorThis arm will consume 2 portions (each 120 g cooked) of conventional burger per week for a 4-week period.
Receives: Behavioral: Conventional burger
Vegan burger groupExperimentalThis arm will consume 2 portions (each 120 g cooked) of vegan burger per week for a 4-week period.
Receives: Behavioral: Vegan burger

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline in homeostasis model of assessment - insulin resistance (HOMA-IR) at 4 weeks

    HOMA-IR will be calculated based on fasting glucose and fasting insulin levels through the Mathews equation. Fasting glucose and insulin will be measured in serum via a photometric method in a biochemical analyzer.

    Measured: 0 (baseline) and 4 weeks

  2. Change from baseline in total cholesterol at 4 weeks

    Total cholesterol will be measured in serum via a photometric method in a biochemical analyzer.

    Measured: 0 (baseline) and 4 weeks

  3. Change from baseline in low-density lipoprotein (LDL) cholesterol at 4 weeks

    LDL cholesterol will be measured in serum via a photometric method in a biochemical analyzer.

    Measured: 0 (baseline) and 4 weeks

  4. Change from baseline in high-density lipoprotein (LDL) cholesterol at 4 weeks

    HDL cholesterol will be measured in serum via a photometric method in a biochemical analyzer.

    Measured: 0 (baseline) and 4 weeks

  5. Change from baseline in triglycerides at 4 weeks

    Triglycerides will be measured in serum via a photometric method in a biochemical analyzer.

    Measured: 0 (baseline) and 4 weeks

  6. Change from baseline in uric acid at 4 weeks

    Uric acid will be measured in serum via a photometric method in a biochemical analyzer.

    Measured: 0 (baseline) and 4 weeks

  7. Change from baseline in urea at 4 weeks

    Urea will be measured in serum via a photometric method in a biochemical analyzer.

    Measured: 0 (baseline) and 4 weeks

  8. Change from baseline in high sensitivity C-reactive protein (hsCRP) at 4 weeks

    hsCRP will be measured in serum via an enzyme-linked immunoassay.

    Measured: 0 (baseline) and 4 weeks

  9. Change from baseline in systolic blood pressure (SBP) at 4 weeks

    SBP will be measured with an automatic device operating on the oscillometric principle.

    Measured: 0 (baseline) and 4 weeks

  10. Change from baseline in diastolic blood pressure (DBP) at 4 weeks

    DBP will be measured with an automatic device operating on the oscillometric principle.

    Measured: 0 (baseline) and 4 weeks

Secondary outcomes (7)
  1. Change from baseline in hematocrit at 4 weeks

    Hematocrit will be measured in a hematology analyzer.

    Measured: 0 (baseline) and 4 weeks

  2. Change from baseline in iron at 4 weeks

    Iron will be measured in serum via a photometric method in a biochemical analyzer.

    Measured: 0 (baseline) and 4 weeks

  3. Change from baseline in ferritin at 4 weeks

    Ferritin will be measured in serum via a chemiluminescent immunoassay in a biochemical analyzer.

    Measured: 0 (baseline) and 4 weeks

  4. Change from baseline in total iron binding capacity at 4 weeks

    Total iron binding capacity will be measured in serum via a photometric method in a biochemical analyzer.

    Measured: 0 (baseline) and 4 weeks

  5. Change from baseline in albumin at 4 weeks

    Albumin will be measured in serum via a photometric method in a biochemical analyzer.

    Measured: 0 (baseline) and 4 weeks

  6. Change from baseline in alanine aminotransferase (ALT) at 4 weeks

    ALT will be measured in serum via a photometric method in a biochemical analyzer.

    Measured: 0 (baseline) and 4 weeks

  7. Change from baseline in gamma-glutamyl transferase (GGT) at 4 weeks

    GGT will be measured in serum via a photometric method in a biochemical analyzer.

    Measured: 0 (baseline) and 4 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Oct 2022
  2. Study start1 Oct 2022
  3. Primary completionMay 2023 (estimated)
  4. Study completionMay 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
Triple blind
Who is masked
Care provider, Investigator, Outcomes assessor
Enrolment
15 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05582720
Sponsor's protocol ID
Γ-3047/17-06-2021
Acronym
VeganBurger
Status last verified
Mar 2023
First submitted
13 Oct 2022
Last updated
7 Mar 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Deidentified participant data will be shared to investigators for the purpose of data meta-analysis, provided that the proposed use has been approved by the Study Principal Investigator. Proposals should be directed to tnomikos@hua.gr. To gain access, data requestors will need to sign a data access agreement.

Questions about this trial

What is this clinical trial studying?

A study testing Conventional burger and Vegan burger in people with Cardiometabolic Health, run by Harokopio University at 1 site in Greece.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 7 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Tzortzis Nomikos, PhD (+302109549100 ext. 305, tnomikos@hua.gr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline in homeostasis model of assessment - insulin resistance (HOMA-IR) at 4 weeks (time frame: 0 (baseline) and 4 weeks). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in